A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

被引:2
|
作者
Rada, Miran [1 ]
Krzywon, Lucyna [1 ]
Petrillo, Stephanie [1 ]
Lazaris, Anthoula [1 ]
Metrakos, Peter [1 ]
机构
[1] McGill Univ, Canc Res Program, Res Inst, Hlth Ctr, Montreal, PQ H4A 3J1, Canada
关键词
CRCLM; angiogenesis; vessel co-option; metformin; tumour recurrence; extrahepatic metastases; VESSEL CO-OPTION; GROWTH; RESECTABILITY; SUPPRESSES; SURVIVAL; GLUCOSE; IMPACT; TUMORS; DRUGS;
D O I
10.3390/biomedicines11030731
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer liver metastases (CRCLMs) have two main histopathological growth patterns (HPGs): desmoplastic (DHGP) and replacement (RHGP). The vascularization in DHGP tumours is angiogenic, while the RHGP tumours exert vessel co-option vasculature. The presence of vessel co-option tumours is associated with poor response to anti-angiogenic agents and chemotherapy, as well as a worse prognosis. Metformin has been shown to influence the progression and vasculature of tumours in different cancers. However, its role in CRCLM is poorly understood. Herein, we conducted a retrospective cohort study to examine the role of metformin in CRCLM. A dataset of 108 patients was screened, of which 20 patients used metformin. The metformin user patients did not use metformin as an anticancer agent. We noticed a significantly lower percentage of CRCLM patients with vessel co-opting RHGP tumours in the population that used metformin compared to CRCLM patients who did not use metformin. Similar results were obtained when we compared the ratio of recurrence and extrahepatic metastases incidence. Moreover, the metformin user patients had significantly higher survival outcome compared to nonusers. Collectively, our data suggest that metformin administration is likely associated with better prognosis of CRCLM.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The role of combined treatment of metastatic colorectal cancer in patients with liver metastases
    Popov, A.
    Gridnev, D.
    Gritskevich, A.
    Trandofilov, M.
    Islamova, D.
    Makarov, V.
    Vozny, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S282 - S282
  • [32] Clinicopathologic and immunohistochemical study of early colorectal cancer with liver metastases
    Okano, K
    Shimoda, T
    Matsumura, Y
    JOURNAL OF GASTROENTEROLOGY, 1999, 34 (03) : 334 - 340
  • [33] Clinicopathologic and immunohistochemical study of early colorectal cancer with liver metastases
    Keiichi Okano
    Tadakazu Shimoda
    Yasuhiro Matsumura
    Journal of Gastroenterology, 1999, 34 : 334 - 340
  • [34] Liver resection for colorectal cancer metastases
    Gallinger, S.
    Biagi, J. J.
    Fletcher, G. G.
    Nhan, C.
    Ruo, L.
    McLeod, R. S.
    CURRENT ONCOLOGY, 2013, 20 (03) : E255 - E265
  • [35] Management of Colorectal Cancer Liver Metastases
    Durden, Jakob A.
    Ziogas, Ioannis A.
    Moris, Dimitrios P.
    Gleisner, Ana L.
    CANCERS, 2024, 16 (02)
  • [36] Treatment of liver metastases of colorectal cancer
    van de Velde, CJH
    ANNALS OF ONCOLOGY, 2005, 16 : 144 - 149
  • [37] Chemotherapy for Colorectal Cancer Liver Metastases
    Alberts, Steven R.
    Wagman, Lawrence D.
    ONCOLOGIST, 2008, 13 (10): : 1063 - 1073
  • [38] Chemotherapy of colorectal cancer liver metastases
    Glimelius, B
    EJC SUPPLEMENTS, 2003, 1 (06): : 173 - 180
  • [39] Macrophages in Colorectal Cancer Liver Metastases
    Cortese, Nina
    Soldani, Cristiana
    Franceschini, Barbara
    Barbagallo, Marialuisa
    Marchesi, Federica
    Torzilli, Guido
    Donadon, Matteo
    CANCERS, 2019, 11 (05)
  • [40] Colorectal cancer: The treatment of liver metastases
    Kemeny, N
    EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY - 21ST ESMO CONGRESS, EDUCATIONAL BOOK, 1996, : 31 - 33